Saturday 17 October 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
6.08
0.32
−5.00%
Follow GYRE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 141.20 | 106.57 |
+8 more quarters Free account |
P/S ratio |
5.70 | 5.44 | 5.41 | 6.15 | |
P/FCF ratio |
0.00 | 207.39 | 0.00 | 450.03 | |
P/Operating CF |
(39.65) | 200.15 | (112.14) | 47.60 | |
P/B ratio |
4.65 | 4.65 | 10.59 | 4.93 | |
Price to Tangible BV |
4.81 | 4.81 | 11.51 | 5.11 | |
EV/Sales |
5.10 | 5.06 | 4.66 | 5.65 | |
EV/EBITDA |
0.00 | 235.25 | 38.79 | 62.60 | |
EV/Operating CF |
(120.29) | 137.05 | 537.99 | 160.67 | |
EV/FCF |
(83.33) | 192.86 | (615.37) | 413.62 | |
Quick Ratio |
3.59 | 3.68 | 5.21 | 5.41 | |
Current Ratio |
4.26 | 4.64 | 6.28 | 6.19 | |
Net Debt/EBITDA |
5.80 | 5.74 | (17.74) | (8.28) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.66 | 0.80 | 0.68 | 0.77 | |
Operating CF/Net income |
1.43 | (0.37) | (7.37) | 3.94 | |
Capex/Depreciation |
(0.87) | (0.26) | (0.19) | (1.86) | |
Interest Coverage |
(15.23) | — | — | — | |
Research and Development Expense of Revenue |
65.75% | 29.92% | (0.32%) | 7.73% | |
Selling, General and Administrative Expense of Revenue |
74.29% | 94.84% | 81.99% | 64.28% | |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.02 | 0.03 | |
Share Based Compensation of Revenue |
7.13% | 11.47% | 13.43% | 2.02% | |
Graham Net Nets |
0.13 | 0.10 | 0.19 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.87 | 1.54 | |
Earnings Yield |
(3.03%) | (1.15%) | 0.71% | 0.94% | |
Free Cash Flow Yield |
(1.07%) | 0.48% | (0.14%) | 0.22% | |
Revenue per Share |
0.29 | 0.25 | 0.38 | 0.34 | |
Operating CF per Share |
(0.17) | 0.03 | (0.06) | 0.16 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.18) | 0.03 | (0.06) | 0.15 | |
Cash per Share |
0.74 | 0.55 | 1.04 | 0.66 | |
Shareholders Equity per Share |
1.64 | 1.50 | 2.11 | 1.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.64 | 1.50 | 2.11 | 1.51 | |
Free Cash Flow |
(18.01) | 3.00 | (5.75) | 13.63 | |
Working Capital |
93.41 | 71.94 | 125.58 | 82.66 | |
Capital Expenditures |
(1.28) | (0.18) | (0.13) | (0.60) | |
Net Current Asset Value |
87.74 | 66.70 | 117.96 | 76.61 | |
EV/EBIT |
0.00 | 0.00 | 47.30 | 81.69 | |
Capex to Sales |
0.04 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 54.91 | 88.88 | |
| Other line items | |||||
Average Receivables |
26.44 | 21.69 | 28.04 | 23.44 | |
Average Payables |
0.65 | 0.19 | 0.72 | 0.43 | |
Average Inventory |
10.14 | 9.62 | 8.25 | 7.62 | |
Average Assets |
175.95 | 145.90 | 172.58 | 142.31 | |
Average Common Equity |
135.97 | 120.64 | 78.97 | 117.94 |
Columns are period end dates